This short article and poster summary takes a deeper look into the 2021 IPOs for biotechnology-based therapeutics being developed by oncology-focused companies, including:
- Antibody-drug conjugates
- Monoclonal antibodies
- Protein-based therapeutics
- Cell and gene therapies
- Other biotechnology-based therapeutics
This article is Part 4 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 and Part 2 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 3 provided a deep dive into the 2021 IPOs for oncology-focused companies developing conventional small molecule therapeutics.
request a trial
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
